Additionally, four cases in our cohort showed two different KRAS gene mutations, suggesting either the existence of two tumor clones, one of which cannot be targeted by KRAS inhibitors, or—in the case that both mutations occur in the same tumor cells—that the mutated KRAS protein structure might not be targeted with the same efficiency. The gene discussed is KRAS; the disease is neoplasm.